31.65USD-3.20%Mkt Cap: 3.66B USDP/E: —Last update: 2026-06-01
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue an…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap3.66B USD
Enterprise Value3.20B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-359.64M USD
Revenue/Share—
Last Price31.65 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees59
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS92686J1060
Valuation
P/E (Trailing)—
P/E (Forward)-7.17
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B5.88
EPS (TTM)-4.15
EPS (Forward)-4.57
52W Range
22.9643% of range43.15
52W High43.15 USD
52W Low22.96 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-56.28%
ROA-50.25%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-278.69M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-4.85%
Net Debt-602.96M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio5.72
Quick Ratio5.67
Book Value/Sh5.567 USD
Cash/Share5.193 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)92.58 USD
Target Range34.00 USD – 125.00 USD
# Analysts19
Ownership
Shares Out.116.11M
Float113.28M
Insiders2.78%
Institutions64.50%
Short Interest
Short Ratio9.8d
Short % Float20.28%
Short % Out.19.19%
Shares Short22.28M
Short (prev mo.)23.11M
Technical
SMA 5032.52 (-2.7%)
SMA 20032.49 (-2.6%)
Beta0.71
S&P 52W Chg27.70%
Avg Vol (30d)2.09M
Avg Vol (10d)1.92M
Technical Indicators
RSI (14)56.2
MACD-0.2758
MACD Signal-0.6082
MACD Hist.+0.3324
BB Upper33.37 USD
BB Middle31.03 USD
BB Lower28.70 USD
BB Width15.04%
ATR (14)1.409 USD
Vol Ratio (20d)0.55x